Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus
Status:
Terminated
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the antiviral effects and safety of clevudine 30 mg
once a day (QD) and 50 mg QD in patients infected with hepatitis B virus (HBV).